Teva Pharmaceutical Industries Limited

NYSE:TEVA

Drug Manufacturers - Specialty & Generic

Healthcare
$42.23 -3.35%

-$1.09 today

Market cap
$49.28B
Beta
0.85
P/E (TTM)
23.1
EPS (TTM)
$1.36
52W Low $14.99High $37.35

Volume 8.86M

Average 6.22M

TEVA Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Teva Pharmaceutical Industries LimitedNYSE: TEVA

Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026

Depreciation & amortization declines year over year

Q2 FY2026 depreciation & amortization of $241M fell 4.0% year over year, behind the -3.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.8% from the prior quarter. Over 3 fiscal years it compounded at -8.5% a year.

Context

  • Depreciation & amortization amounted to 5.8% of revenue in FY2025, down 0.6 pp from a year earlier.
  • Depreciation & amortization increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -4.0% toward the trailing-twelve-month pace of -3.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$241M+0.8% QoQ
Last fiscal yearDec 2025
$1B-5.4% YoY
LTMJun 2026
$989M-3.3% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-4.0%——
1 year-5.4%——
3-year CAGR-8.5%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
1B USD
Year-over-year change
-5.4%
4-year CAGR
-6.8%

Depreciation & Amortization vs competitors

How TEVA compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -3.3% is the 4th highest of 5, against a peer median of +7.2%.
  • Depreciation & amortization amounts to 5.7% of revenue for TEVA, versus a peer median of 6.8%.
TEVA Competitors
Depreciation & Amortization for TEVA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RDYDr. Reddy's Laboratories LimitedLTM Sep 2026₹21.51B INR+12.7%+19.7%6.5%
VTRSViatris Inc.LTM Jun 2026$2.8B USD+1.6%-2.6%19.0%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 2026$989M USD-3.3%-8.5%5.7%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$194.29M USD-20.8%-2.4%6.2%
ALVOAlvotechLTM Mar 2026$39.88M USD+23.2%+22.9%7.1%
Peer median (excluding TEVA) —+7.2%+8.7%6.8%

Competitors are the stored peer set for TEVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income456M(2.5B)(615M)(1.96B)1.42B
Depreciation & Amortization1.33B1.31B1.15B1.06B1B
Deferred Income Tax(120M)(1.06B)(317M)(634M)(671M)
Stock-Based Compensation119M124M121M123M157M
Change in Working Capital(1.7B)1.36B(72M)(435M)(1.37B)
Accounts Receivables(574M)334M12M245M(173M)
Inventory380M(163M)(147M)166M152M
Accounts Payables764M2.01B1.59B258M(15M)
Other Working Capital(2.27B)(828M)(1.53B)(1.1B)(1.33B)
Other Non-Cash Items714M2.37B1.1B3.09B1.11B
Operating Cash Flow798M1.59B1.37B1.25B1.65B
Capital Expenditures(562M)(548M)(526M)(498M)(501M)
Acquisitions (Net)1.96B61M68M28M34M
Purchases of Investments(47M)(1M)(46M)(71M)(57M)
Sales of Investments172M4M040M42M
Other Investing Activities1M1.14B1.47B1.29B1.22B
Investing Cash Flow1.52B656M968M792M737M
Debt Repayment(2.17B)(1.37B)(1.7B)(1.64B)(1.81B)
Common Stock Issued00000
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(6M)(118M)(212M)(150M)(337M)
Financing Cash Flow(2.17B)(1.49B)(1.91B)(1.79B)(2.15B)
Effect of Forex Changes(128M)(123M)(30M)(175M)21M
Net Change in Cash21M636M393M73M256M
Free Cash Flow236M1.04B842M749M1.15B

Teva Pharmaceutical Industries Limited

NYSE:TEVA

Intrinsic Alpha fair value

Locked

Current Price

$42.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.